• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    Orexigen Therapeutics, Inc. (OREX)

    -NasdaqGS
    4.76 Down 0.17(3.45%) Jul 2, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Orexigen Therapeutics, Inc.
    3344 North Torrey Pines Court
    Suite 200
    La Jolla, CA 92037
    United States - Map
    Phone: 858-875-8600
    Fax: 858-875-8650
    Website: http://www.orexigen.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:47

    Business Summary 

    Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Orexigen Therapeutics, Inc.

    Corporate Governance 
    Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 5; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Michael A. Narachi M.S., M.B.A., 56
    Chief Exec. Officer, Pres and Director
    N/AN/A
    Mr. Joseph P. Hagan , 46
    Chief Bus. & Financial Officer and Treasurer
    N/AN/A
    Dr. Preston S. Klassen M.D., M.H.S., 46
    Head of Global Devel. and Exec. VP
    N/AN/A
    Dr. Michael A. Cowley Ph.D., 46
    Co-Founder
    N/AN/A
    Chris Hazuka ,
    Acting Gen. Counsel
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders